BioWorld BioWorld MedTech BioWorld Asia BioWorld Science

BioWorld

PI3K inhibitors slammed again as adcom says no to Secura
Emphasizing April’s vote of concern about the safety of PI3K inhibitors, the U.S. FDA’s Oncologic Drugs Advisory Committee said privately held Secura Bio Inc.’s Copiktra...

More in BioWorld

BioWorld MedTech

Skout clearance opens path to better, more consistent colonoscopies
Colorectal cancer (CRC) is expected to increase steadily through the decade to reach more than 2.2 million cases and 1.1 million deaths by 2030 as two concurrent trends...

More in BioWorld MedTech

BioWorld Science

Early postnatal treatment can delay late-onset neurodegeneration
The mutant gene causing Huntington’s disease (HD) is active from the earliest stages of brain development, even though the pathology is not evident until between 30 and 50...

More in BioWorld Science

BioWorld Asia

Imugene announces AU$80M capital raise to build out immuno-oncology platform
Immuno-oncology company Imugene Ltd. announced an AU$80 million (US$53.9 million) capital raise that will allow the company to add additional studies within its...

More in BioWorld Asia

BioWorld Insider Podcast

BioWorld staff writer Lee Landenberger talks with James Lanthier, the CEO of Mindset Pharma, which is developing what it calls “next-generation” psychedelic medicines to treat neurological and psychiatric disorders.